Loading...
•
Jun 30, 2023
Leap Therapeutics Q2 2023 Earnings Report
Leap Therapeutics reported financial results for the second quarter ended June 30, 2023.
Key Takeaways
Leap Therapeutics reported a net loss of $13.4 million for the second quarter of 2023, compared to $17.0 million for the same period in 2022. The decrease was primarily due to decreased research and development expenses and increased interest income. Cash and cash equivalents totaled $91.4 million at June 30, 2023.
Initiated Part B of the DeFianCe study based on Part A exceeding the threshold of a 20% ORR.
Presented new long-term follow-up data from Part A of the DisTinGuish study at ASCO, demonstrating 19.5 months median overall survival.
Enrollment continues to be strong in the 160 patient randomized controlled Part C of the DisTinGuish study, and completion is expected in the fourth quarter of this year.
Net Loss was $13.4 million, a decrease compared to $17.0 million for the same period in 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...